Respiratory syncytial virus (RSV ... been based on moderate to complex techniques performed in a laboratory (cell culture, nucleic acid amplification and immunofluorescence assays); however ...

Diagnosis is impossible on clinical grounds alone, as the presentation is indistinguishable from other respiratory tract ... have an accuracy comparable to cell culture and deliver results within ...

Health Canada's approval is based on data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults aged 60 years and older in 22 countries. No serious safety ...

Disease surveillance and genomic analyses in northeast China identifies the emerging tick-borne Yezo virus in 2% of 988 ...

while a triple shot that also adds in respiratory syncytial virus (RSV) should also reach the clinic this year. Sanofi has reported positive results a year ago from a phase 1/2 trial of their ...

Meanwhile, COVID activity remained low amid a shift in variant proportions and RSV levels rose in 3 US regions.

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

"We want Jewish life and culture to thrive in Europe ... Health Canada has approved Moderna's mRNA vaccine to protect against ...

Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.